carmustine has been researched along with Recrudescence in 124 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Allogeneic stem cell transplant (SCT) after high-dose conditioning with BEAM/fludarabine/total body irradiation (TBI) in patients with relapsed or refractory lymphoma has shown promising results in a pilot study." | 9.17 | Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI. ( Bucher, C; Buser, A; Gerull, S; Halter, J; Heim, D; O'Meara, A; Passweg, J; Stern, M, 2013) |
| "This phase II trial was designed to define the efficacy of Gliadel wafers in combination with an infusion of O6-benzylguanine (O6-BG) that suppresses tumor O6-alkylguanine-DNA alkyltransferase (AGT) levels in patients with recurrent glioblastoma multiforme for 5 days and to evaluate the safety of this combination therapy." | 9.14 | Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. ( Bigner, DD; Carter, J; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Threatt, S; Vredenburgh, JJ, 2009) |
| "Autologous stem cell transplantation (SCT) with high-dose melphalan (HDM, 200 mg/m2) is the most effective therapy for multiple myeloma." | 9.12 | Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation. ( Comenzo, RL; Dhodapkar, M; Filippa, D; Fleisher, M; Hassoun, H; Kewalramani, T; Klimek, V; Nimer, SD; Reich, L; Teruya-Feldstein, J, 2006) |
| "Forty-four non-Hodgkin's lymphoma and 35 Hodgkin's disease patients 16 to 63 years of age were given intravenous carmustine (BCNU) 600 to 1,050 mg/m2, etoposide 2,400 to 3,000 mg/m2, and cisplatin 200 mg/m2 (BEP) and ABMT." | 9.07 | High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma. ( Bulova, SI; Ciobanu, N; Cooper, BW; Creger, RJ; Crilley, P; Fox, RM; Gucalp, R; Lazarus, HM; Shina, DC; Topolsky, D, 1992) |
| " We present a retrospective analysis of 73 consecutive patients aged over 65 years treated for aggressive or relapsed lymphoma by HDT with carmustine, etoposide, cytarabine and melphalan (BEAM) at full dosage followed by ASCT." | 5.42 | High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma. ( Barriere, J; Borchiellini, D; Boscagli, A; Coso, D; Garnier, G; Gastaud, L; Gutnecht, J; Martin, N; Naman, H; Petit, E; Peyrade, F; Re, D; Rossignol, B; Saudes, L; Thyss, A, 2015) |
| "Anaplastic ependymoma is associated with a higher incidence of tumor recurrence and its prognosis still remains unsatisfactory." | 5.35 | Intracavitary chemotherapy (Gliadel) and oral low-dose etoposide for recurrent anaplastic ependymoma. ( Donati, PA; Genitori, L; Giordano, F; Mussa, F; Sandri, A; Sanzo, M; Sardi, I, 2008) |
| "Allogeneic stem cell transplant (SCT) after high-dose conditioning with BEAM/fludarabine/total body irradiation (TBI) in patients with relapsed or refractory lymphoma has shown promising results in a pilot study." | 5.17 | Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI. ( Bucher, C; Buser, A; Gerull, S; Halter, J; Heim, D; O'Meara, A; Passweg, J; Stern, M, 2013) |
| "This phase II trial was designed to define the efficacy of Gliadel wafers in combination with an infusion of O6-benzylguanine (O6-BG) that suppresses tumor O6-alkylguanine-DNA alkyltransferase (AGT) levels in patients with recurrent glioblastoma multiforme for 5 days and to evaluate the safety of this combination therapy." | 5.14 | Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. ( Bigner, DD; Carter, J; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Threatt, S; Vredenburgh, JJ, 2009) |
| "Autologous stem cell transplantation (SCT) with high-dose melphalan (HDM, 200 mg/m2) is the most effective therapy for multiple myeloma." | 5.12 | Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation. ( Comenzo, RL; Dhodapkar, M; Filippa, D; Fleisher, M; Hassoun, H; Kewalramani, T; Klimek, V; Nimer, SD; Reich, L; Teruya-Feldstein, J, 2006) |
| "Autologous stem cell transplantation after high-dose melphalan for the treatment with multiple myeloma has resulted in prolonged progression-free survival and overall survival in patients under 65 years." | 5.09 | The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. ( Bhagwati, N; Horton, C; Kulkarni, S; Mainwaring, P; Mehta, J; Pandha, H; Powles, R; Singhal, S; Sirohi, B; Treleaven, J, 2000) |
| "Forty-four non-Hodgkin's lymphoma and 35 Hodgkin's disease patients 16 to 63 years of age were given intravenous carmustine (BCNU) 600 to 1,050 mg/m2, etoposide 2,400 to 3,000 mg/m2, and cisplatin 200 mg/m2 (BEP) and ABMT." | 5.07 | High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma. ( Bulova, SI; Ciobanu, N; Cooper, BW; Creger, RJ; Crilley, P; Fox, RM; Gucalp, R; Lazarus, HM; Shina, DC; Topolsky, D, 1992) |
| "Thirty-two evaluable good risk patients with multiple myeloma received a 70-day tapering course of prednisone beginning at a dose of 1." | 5.05 | Response rate and survival in myeloma patients receiving prednisone alone. ( Cornwell, GG; Kyle, RA; Leone, L; McIntyre, OR; Pajak, TF, 1985) |
| "The effects of various regimens of melphalan combination chemotherapy were evaluated in 508 patients with multiple myeloma." | 5.04 | Remission maintenance therapy for multiple myeloma. ( , 1975) |
| " Patients with lymphoma received carmustine 300 mg/m(2), cyclophosphamide 1,500 mg/m(2) on days 2 through 5 (total 6 g/m(2)), and etoposide 700 mg/m(2) per day on days 2 through 4 (total 2,100 mg/m(2))." | 3.81 | Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah's Witnesses. ( Ford, PA; Grant, SJ; Keck, G; Mick, R, 2015) |
| " Graft-versus-host disease prophylaxis consisted of cyclosporine A and alemtuzumab (10-20 mg)." | 3.78 | Radiation-free allogeneic conditioning with fludarabine, carmustine, and thiotepa for acute lymphoblastic leukemia and other hematologic malignancies necessitating enhanced central nervous system activity. ( Bertz, H; Christopoulos, P; Finke, J; Ihorst, G; Marks, R; Wäsch, R, 2012) |
| " Patients who proceeded to haematopoietic stem cell transplants (HDTs) received conditioning therapy with BEAM [for the Hodgkin's Lymphoma (HL) and non-Hodgkin's Lymphoma (NHL) groups], or melphalan 100 mg/m2 and mitoxantrone [for the multiple myeloma (MM) patients]." | 3.73 | Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies. ( Albarello, A; Ballerini, F; Balocco, M; Canepa, L; Canepa, P; Clavio, M; Garrone, A; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Varaldo, R, 2005) |
| "Sixteen children with non-Hodgkin's lymphoma (NHL) who had relapsed were treated with high-dose chemotherapy with BCNU, cyclophosphamide, cytarabine, 6-thioguanine (high-dose chemotherapy [HDC]) and autologous bone marrow transplantation (ABMT)." | 3.67 | High-dose polychemotherapy with autologous bone marrow transplantation in children with relapsed lymphomas. ( Beaujean, F; Hartmann, O; Kalifa, C; Lemerle, J; Parmentier, C; Patte, C; Pein, F, 1984) |
| "Five children with recurrent medulloblastomas were treated with Vincristine, BCNU, Methotrexate and Dexamethasone." | 3.66 | Combination chemotherapy in recurrent medulloblastoma. ( Cohen, ME; Duffner, PK; Freeman, AI; Sinks, LF; Thomas, PR, 1979) |
| "Patients with follicular lymphoma (FL) who do not respond to first-line chemotherapy or those who relapse after obtaining a remission have a poor outcome with standard treatment." | 2.69 | Salvage chemotherapy with IAPVP-16 for advanced refractory or relapsed follicular lymphomas. ( Brunet, S; Domingo-Albós, A; López, R; Martino, R; Sierra, J; Sureda, A, 1999) |
| "Ten patients who relapsed are alive a median of 31 months (range, 6-47) after relapse." | 2.69 | High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma. ( Buckner, CD; Rhinehart, S; Schwartzberg, L; Weaver, CH; West, J; West, WH; Zhen, B, 1998) |
| "At ABMT, 17 patients were in untreated relapse and one was in third complete remission (CR)." | 2.68 | Autologous bone marrow transplantation for patients with acute myeloblastic leukemia in relapse after autologous blood stem cell transplantation. ( Bonanad, S; Carral, A; de la Rubia, J; Jarque, I; Larrea, L; López, F; Martín, G; Martínez, J; Picón, I; Sanz, GF; Sanz, MA; Sempere, A; Soler, MA, 1996) |
| "Twenty-three patients were treated in first relapse and 10 in second or subsequent relapse; 21 received mini-BEAM as their first salvage regimen." | 2.68 | Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. ( Brandwein, JM; Colwill, R; Couture, F; Crump, M; Danish, R; Keating, A; Scott, JG; Stewart, AK; Sutcliffe, SB; Sutton, DM, 1995) |
| "Fourteen patients with relapsed Hodgkin's disease responded to a salvage therapy with Dexa-BEAM (dexamethasone, BCNU, etoposide, Ara-C and melphalan)." | 2.67 | Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) subsequent to chemotherapy improves collection of blood stem cells for autografting in patients not eligible for bone marrow harvest. ( Egerer, G; Ehrhardt, R; Haas, R; Hohaus, S; Hunstein, W; Witt, B, 1992) |
| " We present a retrospective analysis of 73 consecutive patients aged over 65 years treated for aggressive or relapsed lymphoma by HDT with carmustine, etoposide, cytarabine and melphalan (BEAM) at full dosage followed by ASCT." | 1.42 | High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma. ( Barriere, J; Borchiellini, D; Boscagli, A; Coso, D; Garnier, G; Gastaud, L; Gutnecht, J; Martin, N; Naman, H; Petit, E; Peyrade, F; Re, D; Rossignol, B; Saudes, L; Thyss, A, 2015) |
| "Adult Langerhans cell histiocytosis (LCH) usually follows a favorable course." | 1.38 | [Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transp ( Adam, Z; Adamová, Z; Brejcha, M; Hájek, R; Kodet, R; Koukalová, R; Krejčí, M; Mayer, J; Moulis, M; Nebeský, T; Pour, L; Rehák, Z; Szturz, P; Zahradová, L, 2012) |
| "Patients with Hodgkin lymphoma (HL) had a higher response rate compared to those with diffuse large B cell lymphoma (DLBCL) (63% vs." | 1.38 | Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL. ( Ardeshna, K; Kayani, I; Linch, DC; Lowry, L; Moore, S; Peggs, K; Qian, W; Thomson, K, 2012) |
| "Melphalan dose was used as surrogate for the entire regimen." | 1.35 | Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma. ( Ansell, SM; Costa, LJ; Inwards, DJ; Johnston, PB; Litzow, MR; Micallef, IN; Porrata, LF, 2008) |
| "Anaplastic ependymoma is associated with a higher incidence of tumor recurrence and its prognosis still remains unsatisfactory." | 1.35 | Intracavitary chemotherapy (Gliadel) and oral low-dose etoposide for recurrent anaplastic ependymoma. ( Donati, PA; Genitori, L; Giordano, F; Mussa, F; Sandri, A; Sanzo, M; Sardi, I, 2008) |
| "Patients who had disease bulk at recurrence that measured > 5 cm received involved-field radiation post-ASCT." | 1.33 | Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation ( Crump, M; Keating, A; Kuruvilla, J; Nagy, T; Pintilie, M; Tsang, R, 2006) |
| "Mini-BEAM/HSC is an effective treatment for lymphoma relapses after allogeneic HSCT, but optimal strategies of remission consolidation and prevention of treatment-related complications are needed to improve outcome." | 1.32 | Treatment of lymphoma relapses after allogeneic hematopoietic stem cell transplantation with intensive chemotherapy followed by infusion of hematopoietic stem cell from the original donor. ( Au, WY; Chan, EC; Kwong, YL; Leung, AY; Liang, R; Lie, AK; Ooi, GC; Siu, LL, 2003) |
| "46 patients with Hodgkin's disease received Dexa-BEAM chemotherapy followed by radiotherapy." | 1.31 | [The 1st results of the combined therapy of recurrent and refractory forms of lymphogranulomatosis (polychemotherapy, radiation therapy and the removal of the residual mediastinal formation)]. ( Dzhumabaeva, BT; Efimov, IV; Kaplanskaia, IB; Margolin, OV; Moiseeva, TN; Pivnik, AV; Rasstrigin, NA; Roshchina, LS; Shavlokhov, VS; Sotnikov, VM; Stroiakovskiĭ, DL, 2000) |
| "We transplanted 42 patients with Hodgkin's disease between 1990-1998." | 1.31 | [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer]. ( Avigdor, A; Ben-Bassat, I; Grotto, I; Hardan, I; Raanani, P; Shpilberg, O, 2000) |
| "First relapse was treated with high-dose BEAM chemotherapy and autologous peripheral blood stem cell transplantation (PBSCT)." | 1.30 | Treatment of relapsed non-Hodgkin's lymphoma after BEAM chemotherapy and autologous transplantation by BU/CY chemotherapy and salvage transplantation. ( Behringer, D; Fetscher, S; Finke, J; Kanz, L; Lange, W; Lübbert, M; Mertelsmann, R, 1997) |
| "Eleven patients with acute myeloblastic leukemia (AML) beyond the first complete remission or chronic myelogenous leukemia (CML) not in first chronic phase received an association of 13." | 1.29 | Total body irradiation and high-dose cyclophosphamide, BCNU and VP-16 (CBV) as a new preparatory regimen for allogeneic bone marrow transplantation in patients with advanced hematologic malignancies. ( Bourdin, S; Harousseau, JL; Le Tortorec, S; Mahe, B; Mahe, JM; Mechinaud-Lacroix, F; Milpied, N; Moreau, P; Rapp, MJ; Wu, DP, 1994) |
| " Adverse prognostic factors for failure-free survival include high LDH at the time of autologous BMT, chemotherapy-refractory disease and multiple prior relapses." | 1.29 | High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity. ( Andersson, B; Dimopoulos, M; Giralt, S; Khouri, I; Mehra, R; Przepiorka, D; Rodriguez, M; Suki, S; Tabocoff, J; van Besien, K, 1995) |
| "CBV and PSCT for patients with relapsed Hodgkin's diseases who have marrow hypocellularity in traditional harvest sites or histopathologic evidence of BM metastases can result in long-term event-free survival." | 1.28 | High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease. ( Armitage, JO; Bierman, PJ; Kessinger, A; Vose, JM, 1991) |
| "Fifty patients with advanced-stage Hodgkin's disease (HD) who relapsed or failed to respond to multiple regimens of combination chemotherapy were entered onto two autologous bone marrow transplantation (AuBMT) protocols." | 1.28 | Autologous bone marrow transplantation for refractory or relapsed Hodgkin's disease: the Memorial Sloan-Kettering Cancer Center experience using high-dose chemotherapy with or without hyperfractionated accelerated total lymphoid irradiation. ( Gulati, S; Yahalom, J, 1991) |
| "Twenty-one patients had malignant lymphomas, three, acute lymphoblastic leukemia (ALL), and two, malignant thymomas." | 1.27 | Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies. ( Blaise, D; Gaspard, MH; Gastaut, JA; Maraninchi, D; Michel, G; Novakovitch, G; Rossi, JF; Stoppa, AM; Tubiana, N; Weiller, PJ, 1988) |
| "Thirty patients with relapsed Hodgkin's disease were treated with high-dose cyclophosphamide, carmustine, and etoposide (CBV) and autologous bone marrow transplantation." | 1.27 | High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease. ( Armitage, JO; Cabanillas, FF; Dicke, KA; Horwitz, LJ; Jagannath, S; Spitzer, G; Vellekoop, L; Zander, AR, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (13.71) | 18.7374 |
| 1990's | 36 (29.03) | 18.2507 |
| 2000's | 39 (31.45) | 29.6817 |
| 2010's | 29 (23.39) | 24.3611 |
| 2020's | 3 (2.42) | 2.80 |
| Authors | Studies |
|---|---|
| Arshad, S | 1 |
| Fang, X | 1 |
| Ahn, KW | 1 |
| Kaur, M | 1 |
| Scordo, M | 1 |
| Sauter, CS | 1 |
| Furqan, F | 1 |
| Awan, FT | 1 |
| Hamadani, M | 1 |
| Qasrawi, A | 1 |
| Arora, R | 1 |
| Ramlal, R | 1 |
| Munker, R | 1 |
| Hildebrandt, GC | 1 |
| Alencar, AJ | 1 |
| Moskowitz, CH | 3 |
| Ciochetto, C | 1 |
| Botto, B | 1 |
| Passera, R | 1 |
| Bellò, M | 1 |
| Benevolo, G | 1 |
| Boccomini, C | 1 |
| Castellino, A | 1 |
| Chiappella, A | 1 |
| Freilone, R | 2 |
| Nicolosi, M | 1 |
| Orsucci, L | 1 |
| Pecoraro, C | 1 |
| Pregno, P | 1 |
| Bisi, G | 1 |
| Vitolo, U | 2 |
| Tsang, ES | 1 |
| Villa, D | 1 |
| Loscocco, F | 1 |
| Visani, G | 2 |
| Power, M | 1 |
| Guiducci, B | 1 |
| Clissa, C | 1 |
| Song, K | 1 |
| Toze, C | 1 |
| Abou Mourad, Y | 1 |
| Sutherland, H | 1 |
| Sanford, D | 1 |
| Nantel, SH | 1 |
| Sehn, LH | 1 |
| Scott, DW | 1 |
| Savage, KJ | 1 |
| Connors, JM | 2 |
| Gerrie, AS | 1 |
| Isidori, A | 2 |
| Salvi, F | 1 |
| Luminari, S | 1 |
| Tucci, A | 1 |
| Massidda, S | 1 |
| Liberati, AM | 1 |
| Stelitano, C | 1 |
| Zanni, M | 1 |
| Re, A | 1 |
| Centurioni, R | 1 |
| Musuraca, G | 1 |
| Nassi, L | 1 |
| Patti, C | 1 |
| Arcari, A | 1 |
| Tani, M | 1 |
| Pulsoni, A | 1 |
| Pavone, V | 1 |
| Volpetti, S | 1 |
| Peli, A | 1 |
| Evangelista, A | 1 |
| Spina, M | 1 |
| Ladetto, M | 1 |
| Merli, F | 1 |
| Vose, JM | 4 |
| Carter, S | 1 |
| Burns, LJ | 1 |
| Ayala, E | 1 |
| Press, OW | 1 |
| Stadtmauer, EA | 2 |
| Mineshi, S | 1 |
| Ambinder, R | 1 |
| Fenske, T | 1 |
| Horowitz, M | 1 |
| Fisher, R | 1 |
| Tomblyn, M | 1 |
| William, BM | 2 |
| Allen, MS | 1 |
| Loberiza, FR | 2 |
| Bociek, RG | 2 |
| Bierman, PJ | 4 |
| Armitage, JO | 5 |
| Shankar, A | 1 |
| Hayward, J | 1 |
| Kirkwood, A | 1 |
| McCarthy, K | 1 |
| Hewitt, M | 1 |
| Morland, B | 1 |
| Daw, S | 1 |
| Cecchin, D | 1 |
| Schiorlin, I | 1 |
| Della Puppa, A | 1 |
| Lombardi, G | 1 |
| Zucchetta, P | 1 |
| Bodanza, V | 1 |
| Gardiman, MP | 1 |
| Rolma, G | 1 |
| Frigo, AC | 1 |
| Bui, F | 1 |
| Pellegrini, C | 1 |
| Maglie, R | 1 |
| Argnani, L | 1 |
| Pileri, S | 1 |
| Zinzani, PL | 2 |
| Garfin, PM | 1 |
| Link, MP | 1 |
| Donaldson, SS | 1 |
| Advani, RH | 1 |
| Luna-Fineman, S | 1 |
| Kharbanda, S | 1 |
| Porteus, M | 1 |
| Weinberg, KI | 1 |
| Agarwal-Hashmi, R | 1 |
| Kirschey, S | 1 |
| Flohr, T | 1 |
| Wolf, HH | 1 |
| Frickhofen, N | 1 |
| Gramatzki, M | 1 |
| Link, H | 1 |
| Basara, N | 1 |
| Peter, N | 1 |
| Meyer, RG | 1 |
| Schmitz, N | 2 |
| Weidmann, E | 1 |
| Banat, A | 1 |
| Schulz, A | 1 |
| Kolbe, K | 1 |
| Derigs, G | 1 |
| Theobald, M | 1 |
| Hess, G | 1 |
| Martin, N | 1 |
| Borchiellini, D | 1 |
| Coso, D | 1 |
| Gastaud, L | 1 |
| Boscagli, A | 1 |
| Saudes, L | 1 |
| Re, D | 1 |
| Gutnecht, J | 1 |
| Garnier, G | 1 |
| Petit, E | 1 |
| Barriere, J | 1 |
| Naman, H | 1 |
| Rossignol, B | 1 |
| Thyss, A | 1 |
| Peyrade, F | 1 |
| Ford, PA | 1 |
| Grant, SJ | 1 |
| Mick, R | 1 |
| Keck, G | 1 |
| Caimi, PF | 1 |
| Silva Rondon, CH | 1 |
| Fu, P | 1 |
| Cooper, BW | 2 |
| Campagnaro, EL | 1 |
| Gerson, SL | 1 |
| Reese-Koc, J | 1 |
| Fox, R | 1 |
| Creger, RJ | 2 |
| de Lima, M | 2 |
| Lazarus, HM | 2 |
| Rabitsch, W | 1 |
| Bojic, M | 1 |
| Wohlfarth, P | 1 |
| Leiner, M | 1 |
| Schörgenhofer, C | 1 |
| Kalhs, P | 1 |
| Schulenburg, A | 1 |
| Sillaber, C | 1 |
| Mitterbauer, M | 1 |
| Sperr, WR | 1 |
| Jäger, U | 1 |
| Skrabs, K | 1 |
| Greinix, H | 1 |
| Hermann, A | 1 |
| Lamm, W | 1 |
| Christofides, A | 1 |
| Costa, LJ | 1 |
| Micallef, IN | 1 |
| Inwards, DJ | 1 |
| Johnston, PB | 1 |
| Porrata, LF | 1 |
| Litzow, MR | 1 |
| Ansell, SM | 1 |
| Quinn, JA | 1 |
| Jiang, SX | 1 |
| Carter, J | 1 |
| Reardon, DA | 1 |
| Desjardins, A | 1 |
| Vredenburgh, JJ | 1 |
| Rich, JN | 1 |
| Gururangan, S | 1 |
| Friedman, AH | 1 |
| Bigner, DD | 1 |
| Sampson, JH | 1 |
| McLendon, RE | 1 |
| Herndon, JE | 1 |
| Threatt, S | 1 |
| Friedman, HS | 1 |
| Eckrich, MJ | 1 |
| Domm, J | 1 |
| Ho, R | 1 |
| Whitlock, JA | 1 |
| Frangoul, H | 1 |
| Barosi, G | 1 |
| Fanti, S | 1 |
| Gianni, AM | 1 |
| Martelli, M | 1 |
| Petrini, M | 1 |
| Tura, S | 1 |
| Zinno, F | 1 |
| Landi, F | 1 |
| Aureli, V | 1 |
| Cometa, AM | 1 |
| Scerpa, MC | 1 |
| Caniglia, M | 1 |
| Pinto, RM | 1 |
| Rana, I | 1 |
| Balduino, G | 1 |
| Miele, MJ | 1 |
| Isacchi, G | 1 |
| Linch, DC | 4 |
| Yung, L | 1 |
| Smith, P | 1 |
| Maclennan, K | 1 |
| Jack, A | 1 |
| Hancock, B | 1 |
| Cunningham, D | 2 |
| Hoskin, P | 1 |
| Qian, W | 2 |
| Holte, H | 1 |
| Boesen, AM | 1 |
| Grigg, A | 1 |
| Browett, P | 1 |
| Trneny, M | 1 |
| Harris, RE | 1 |
| Termuhlen, AM | 1 |
| Smith, LM | 1 |
| Lynch, J | 1 |
| Henry, MM | 1 |
| Perkins, SL | 1 |
| Gross, TG | 1 |
| Warkentin, P | 1 |
| Vlachos, A | 1 |
| Harrison, L | 1 |
| Cairo, MS | 1 |
| Xu, J | 1 |
| Ji, BX | 1 |
| Su, L | 1 |
| Dong, HQ | 1 |
| Sun, WL | 1 |
| Wan, SG | 1 |
| Liu, YO | 1 |
| Zhang, P | 1 |
| Liu, CY | 1 |
| Hohloch, K | 1 |
| Sahlmann, CO | 1 |
| Lakhani, VJ | 1 |
| Wulf, G | 1 |
| Glass, B | 1 |
| Hasenkamp, J | 1 |
| Meller, J | 1 |
| Riggert, J | 1 |
| Trümper, L | 1 |
| Griesinger, F | 1 |
| Shimoni, A | 1 |
| Avivi, I | 1 |
| Rowe, JM | 2 |
| Yeshurun, M | 1 |
| Levi, I | 1 |
| Or, R | 1 |
| Patachenko, P | 1 |
| Avigdor, A | 2 |
| Zwas, T | 1 |
| Nagler, A | 1 |
| Moore, S | 1 |
| Kayani, I | 1 |
| Peggs, K | 1 |
| Lowry, L | 1 |
| Thomson, K | 1 |
| Ardeshna, K | 1 |
| Christopoulos, P | 1 |
| Bertz, H | 1 |
| Ihorst, G | 1 |
| Marks, R | 1 |
| Wäsch, R | 1 |
| Finke, J | 3 |
| Adam, Z | 1 |
| Rehák, Z | 1 |
| Koukalová, R | 1 |
| Szturz, P | 1 |
| Krejčí, M | 1 |
| Pour, L | 1 |
| Zahradová, L | 1 |
| Moulis, M | 1 |
| Kodet, R | 1 |
| Nebeský, T | 1 |
| Brejcha, M | 1 |
| Adamová, Z | 1 |
| Hájek, R | 1 |
| Mayer, J | 1 |
| Kasenda, B | 1 |
| Schorb, E | 1 |
| Fritsch, K | 1 |
| Illerhaus, G | 1 |
| Geisler, CH | 1 |
| Kolstad, A | 1 |
| Laurell, A | 1 |
| Jerkeman, M | 1 |
| Räty, R | 1 |
| Andersen, NS | 1 |
| Pedersen, LB | 1 |
| Eriksson, M | 1 |
| Nordström, M | 1 |
| Kimby, E | 1 |
| Bentzen, H | 1 |
| Kuittinen, O | 2 |
| Lauritzsen, GF | 1 |
| Nilsson-Ehle, H | 1 |
| Ralfkiaer, E | 1 |
| Ehinger, M | 1 |
| Sundström, C | 1 |
| Delabie, J | 1 |
| Karjalainen-Lindsberg, ML | 1 |
| Brown, P | 1 |
| Elonen, E | 2 |
| O'Meara, A | 1 |
| Halter, J | 1 |
| Heim, D | 1 |
| Gerull, S | 1 |
| Bucher, C | 1 |
| Passweg, J | 1 |
| Buser, A | 1 |
| Stern, M | 1 |
| Enke, C | 1 |
| Hankins, J | 1 |
| Chan, WC | 1 |
| Weisenburger, DD | 1 |
| Oinonen, R | 1 |
| Jantunen, E | 1 |
| Itälä, M | 1 |
| Lehtinen, T | 1 |
| Franssila, K | 1 |
| Wiklund, T | 1 |
| Glossmann, JP | 2 |
| Josting, A | 3 |
| Pfistner, B | 2 |
| Paulus, U | 1 |
| Engert, A | 3 |
| Locatelli, F | 1 |
| Labopin, M | 2 |
| Ortega, J | 1 |
| Meloni, G | 1 |
| Dini, G | 1 |
| Messina, C | 1 |
| Yaniv, I | 1 |
| Fagioli, F | 1 |
| Castel, V | 1 |
| Shaw, PJ | 1 |
| Ferrant, A | 1 |
| Pession, A | 1 |
| Sociè, G | 1 |
| Frassoni, F | 1 |
| Kremens, B | 1 |
| Wieland, R | 1 |
| Reinhard, H | 1 |
| Neubert, D | 1 |
| Beck, JD | 1 |
| Klingebiel, T | 1 |
| Bornfeld, N | 1 |
| Havers, W | 1 |
| Rossi, HA | 1 |
| Becker, PS | 1 |
| Emmons, RV | 1 |
| Westervelt, P | 1 |
| Levy, W | 1 |
| Liu, Q | 1 |
| Clark, Y | 1 |
| Ballen, K | 1 |
| Laport, GG | 1 |
| Levine, BL | 1 |
| Schuster, SJ | 1 |
| Luger, SM | 1 |
| Grupp, S | 1 |
| Bunin, N | 1 |
| Strobl, FJ | 1 |
| Cotte, J | 1 |
| Zheng, Z | 1 |
| Gregson, B | 1 |
| Rivers, P | 1 |
| Vonderheide, RH | 1 |
| Liebowitz, DN | 1 |
| Porter, DL | 1 |
| June, CH | 1 |
| Au, WY | 1 |
| Lie, AK | 1 |
| Siu, LL | 1 |
| Chan, EC | 1 |
| Ooi, GC | 1 |
| Leung, AY | 1 |
| Liang, R | 1 |
| Kwong, YL | 1 |
| Kang, HJ | 1 |
| Shin, HY | 1 |
| Choi, HS | 1 |
| Han, KS | 1 |
| Ahn, HS | 1 |
| Dawson, LA | 1 |
| Saito, NG | 1 |
| Ratanatharathorn, V | 1 |
| Uberti, JP | 1 |
| Adams, PT | 1 |
| Ayash, LJ | 1 |
| Reynolds, CM | 1 |
| Silver, SM | 1 |
| Schipper, MJ | 1 |
| Lichter, AS | 1 |
| Eisbruch, A | 1 |
| Rudolph, C | 1 |
| Mapara, M | 1 |
| Sieniawski, M | 1 |
| Sienawski, M | 1 |
| Sieber, M | 2 |
| Kirchner, HH | 1 |
| Dörken, B | 1 |
| Hossfeld, DK | 1 |
| Kisro, J | 1 |
| Metzner, B | 1 |
| Berdel, WE | 1 |
| Diehl, V | 3 |
| Jabbour, E | 1 |
| Peslin, N | 1 |
| Arnaud, P | 1 |
| Ferme, C | 2 |
| Carde, P | 1 |
| Vantelon, JM | 1 |
| Bocaccio, C | 1 |
| Bourhis, JH | 2 |
| Koscielny, S | 1 |
| Ribrag, V | 1 |
| Clavio, M | 1 |
| Garrone, A | 1 |
| Pierri, I | 1 |
| Michelis, GL | 1 |
| Balocco, M | 1 |
| Albarello, A | 1 |
| Varaldo, R | 1 |
| Canepa, P | 1 |
| Miglino, M | 1 |
| Ballerini, F | 1 |
| Canepa, L | 1 |
| Gobbi, M | 1 |
| Brevet, M | 1 |
| Garidi, R | 1 |
| Gruson, B | 1 |
| Royer, B | 1 |
| Vaida, I | 1 |
| Damaj, G | 1 |
| Comenzo, RL | 1 |
| Hassoun, H | 1 |
| Kewalramani, T | 1 |
| Klimek, V | 1 |
| Dhodapkar, M | 1 |
| Reich, L | 1 |
| Teruya-Feldstein, J | 1 |
| Fleisher, M | 1 |
| Filippa, D | 1 |
| Nimer, SD | 2 |
| Kuruvilla, J | 1 |
| Nagy, T | 1 |
| Pintilie, M | 1 |
| Tsang, R | 1 |
| Keating, A | 3 |
| Crump, M | 3 |
| Stewart, DA | 1 |
| Bahlis, N | 1 |
| Valentine, K | 1 |
| Balogh, A | 1 |
| Savoie, L | 1 |
| Morris, DG | 1 |
| Jones, A | 1 |
| Brown, C | 1 |
| Russell, JA | 1 |
| Canales, MA | 3 |
| Martin, A | 2 |
| Caballero, D | 1 |
| Hernandez-Navarro, F | 3 |
| Castagna, L | 1 |
| Magagnoli, M | 1 |
| Balzarotti, M | 1 |
| Sarina, B | 1 |
| Siracusano, L | 1 |
| Nozza, A | 1 |
| Todisco, E | 1 |
| Bramanti, S | 1 |
| Mazza, R | 1 |
| Russo, F | 1 |
| Timofeeva, I | 1 |
| Santoro, A | 1 |
| Torjman, L | 1 |
| Ladeb, S | 1 |
| Lakhal, A | 1 |
| Ben Othman, T | 1 |
| Abdelkefi, A | 1 |
| Ben Abdeladhim, A | 1 |
| Thomson, KJ | 1 |
| Peggs, KS | 1 |
| Blundell, E | 1 |
| Goldstone, AH | 3 |
| Sirohi, B | 2 |
| Powles, R | 2 |
| Murphy, F | 1 |
| Arkenau, T | 1 |
| Norman, A | 1 |
| Oates, J | 1 |
| Wotherspoon, A | 1 |
| Horwich, A | 1 |
| Sardi, I | 1 |
| Sanzo, M | 1 |
| Giordano, F | 1 |
| Sandri, A | 1 |
| Mussa, F | 1 |
| Donati, PA | 1 |
| Genitori, L | 1 |
| Bonnet, JD | 1 |
| Alexanian, R | 1 |
| Salmon, SE | 2 |
| Haut, A | 1 |
| Dixon, DO | 1 |
| Hochberg, FH | 1 |
| Parker, LM | 1 |
| Takvorian, T | 1 |
| Canellos, GP | 1 |
| Zervas, NT | 1 |
| Hartmann, O | 2 |
| Pein, F | 1 |
| Beaujean, F | 2 |
| Kalifa, C | 2 |
| Patte, C | 1 |
| Parmentier, C | 1 |
| Lemerle, J | 1 |
| Philip, T | 2 |
| Guglielmi, C | 2 |
| Hagenbeek, A | 2 |
| Somers, R | 2 |
| Van der Lelie, H | 1 |
| Bron, D | 1 |
| Sonneveld, P | 1 |
| Gisselbrecht, C | 2 |
| Cahn, JY | 1 |
| Harousseau, JL | 2 |
| van Besien, K | 2 |
| Tabocoff, J | 1 |
| Rodriguez, M | 1 |
| Andersson, B | 2 |
| Mehra, R | 2 |
| Przepiorka, D | 1 |
| Dimopoulos, M | 1 |
| Giralt, S | 2 |
| Suki, S | 1 |
| Khouri, I | 2 |
| Vaughan, WP | 1 |
| Kris, E | 1 |
| Vose, J | 1 |
| Gwilt, P | 1 |
| Wöber, C | 1 |
| Schmidbauer, M | 1 |
| Podreka, I | 1 |
| Wenger, S | 1 |
| Pafflmeyer, N | 1 |
| Deecke, L | 1 |
| Reece, DE | 2 |
| Phillips, GL | 1 |
| Colwill, R | 1 |
| Couture, F | 1 |
| Danish, R | 1 |
| Stewart, AK | 2 |
| Sutton, DM | 1 |
| Scott, JG | 1 |
| Sutcliffe, SB | 1 |
| Brandwein, JM | 1 |
| Mills, W | 1 |
| Chopra, R | 1 |
| McMillan, A | 1 |
| Pearce, R | 1 |
| Wu, DP | 1 |
| Milpied, N | 1 |
| Moreau, P | 1 |
| Mechinaud-Lacroix, F | 1 |
| Mahe, B | 1 |
| Le Tortorec, S | 1 |
| Rapp, MJ | 1 |
| Bourdin, S | 1 |
| Mahe, JM | 1 |
| Ahmed, T | 1 |
| Lake, D | 1 |
| Feldman, E | 1 |
| Seiter, K | 1 |
| Helson, L | 1 |
| Mittelman, A | 1 |
| Puccio, C | 1 |
| Chun, H | 1 |
| Grima, K | 1 |
| Akhtar, T | 1 |
| Bessell, EM | 1 |
| Graus, F | 1 |
| Punt, JA | 1 |
| Firth, JL | 1 |
| Hope, DT | 1 |
| Moloney, AJ | 1 |
| Lopez-Guillermo, A | 1 |
| Villa, S | 1 |
| Lumley, MA | 1 |
| Milligan, DW | 1 |
| Knechtli, CJ | 1 |
| Long, SG | 1 |
| Billingham, LJ | 1 |
| McDonald, DF | 1 |
| de la Rubia, J | 1 |
| Sanz, GF | 1 |
| Martín, G | 1 |
| Sempere, A | 1 |
| Picón, I | 1 |
| Carral, A | 1 |
| Larrea, L | 1 |
| Martínez, J | 1 |
| Soler, MA | 1 |
| Bonanad, S | 1 |
| López, F | 1 |
| Jarque, I | 1 |
| Sanz, MA | 1 |
| Hochberg, F | 1 |
| Prados, M | 1 |
| Russell, C | 1 |
| Weissman, D | 1 |
| Evans, R | 1 |
| Cook, P | 1 |
| Burton, G | 1 |
| Eisenberg, PD | 1 |
| Valenzuela, R | 1 |
| Verkh, L | 1 |
| Fetscher, S | 1 |
| Lübbert, M | 1 |
| Kanz, L | 1 |
| Behringer, D | 1 |
| Mertelsmann, R | 1 |
| Lange, W | 1 |
| Uss, AL | 2 |
| Milanovich, NF | 2 |
| Snegir', VM | 2 |
| Skriagin, AE | 1 |
| Zmachinskiĭ, VA | 2 |
| Batan, ZE | 2 |
| Girouard, C | 1 |
| Dufresne, J | 1 |
| Imrie, K | 1 |
| Brandwein, J | 1 |
| Prince, HM | 1 |
| Pantolony, D | 1 |
| Stiff, PJ | 1 |
| Dahlberg, S | 1 |
| Forman, SJ | 1 |
| McCall, AR | 1 |
| Horning, SJ | 1 |
| Nademanee, AP | 1 |
| Blume, KG | 2 |
| LeBlanc, M | 1 |
| Fisher, RI | 1 |
| Popat, U | 1 |
| Przepiork, D | 1 |
| Champlin, R | 1 |
| Pugh, W | 1 |
| Amin, K | 1 |
| Rodriguez, J | 1 |
| Romaguera, J | 1 |
| Rodriguez, A | 1 |
| Preti, A | 1 |
| Claxton, D | 1 |
| Donato, M | 1 |
| Anderlini, P | 1 |
| Gajewski, J | 1 |
| Cabanillas, F | 1 |
| Ptuskin, VV | 1 |
| Demina, EA | 1 |
| Chervonobab, IuV | 1 |
| Tupitsyn, NN | 1 |
| Larionova, VB | 1 |
| Kondrat'eva, NE | 1 |
| Andreeva, LA | 1 |
| Mkheidze, DM | 1 |
| Chimishkian, KL | 1 |
| Weaver, CH | 1 |
| Schwartzberg, L | 1 |
| Rhinehart, S | 1 |
| West, J | 1 |
| Zhen, B | 1 |
| West, WH | 1 |
| Buckner, CD | 1 |
| Mandanas, RA | 1 |
| Saez, RA | 1 |
| Epstein, RB | 1 |
| Confer, DL | 1 |
| Selby, GB | 1 |
| Fouillard, L | 1 |
| Laporte, JP | 1 |
| Lesage, S | 1 |
| Isnard, F | 1 |
| Douay, L | 1 |
| Lopez, M | 1 |
| Aoudjhane, M | 1 |
| Zunic, P | 1 |
| Cheron, N | 1 |
| Stachowiak, J | 1 |
| Lemonnier, MP | 1 |
| Andreu, G | 1 |
| Belkacemi, Y | 1 |
| Noël-Walter, MP | 1 |
| Morel, P | 2 |
| Fenaux, P | 1 |
| Jouet, JP | 1 |
| Bauters, F | 1 |
| Najman, A | 1 |
| Gorin, NC | 1 |
| Lancet, JE | 1 |
| Rapoport, AP | 1 |
| Brasacchio, R | 1 |
| Eberly, S | 1 |
| Raubertas, RF | 1 |
| Linder, T | 1 |
| Muhs, A | 1 |
| Duerst, RE | 1 |
| Abboud, CN | 1 |
| Packman, CH | 1 |
| DiPersio, JF | 1 |
| Constine, LS | 1 |
| Liesveld, JL | 1 |
| Blay, J | 1 |
| Gomez, F | 1 |
| Sebban, C | 1 |
| Bachelot, T | 1 |
| Biron, P | 1 |
| Chauvin, F | 1 |
| Barta, A | 1 |
| Batai, A | 1 |
| Torbagyi, E | 1 |
| Sipos, A | 1 |
| Lengyel, L | 1 |
| Petranyi, GG | 1 |
| Paloczi, K | 1 |
| Kelemen, E | 1 |
| Reiser, M | 1 |
| Dias Wickramanayake, P | 1 |
| Draube, A | 1 |
| Scheid, C | 1 |
| Tesch, H | 1 |
| Wolf, J | 1 |
| Rolhion, C | 1 |
| Penault-Llorca, F | 1 |
| Kemeny, JL | 1 |
| Kwiatkowski, F | 1 |
| Lemaire, JJ | 1 |
| Chollet, P | 1 |
| Finat-Duclos, F | 1 |
| Verrelle, P | 1 |
| López, R | 1 |
| Martino, R | 1 |
| Brunet, S | 1 |
| Sureda, A | 1 |
| Domingo-Albós, A | 1 |
| Sierra, J | 1 |
| Fleming, DR | 1 |
| Wolff, SN | 2 |
| Fay, JW | 2 |
| Brown, RA | 1 |
| Lynch, JP | 1 |
| Bolwell, BJ | 1 |
| Stevens, DA | 1 |
| Goodman, SA | 1 |
| Greer, JP | 3 |
| Stein, RS | 2 |
| Pineiro, LA | 1 |
| Collins, RH | 1 |
| Goldsmith, LJ | 1 |
| Herzig, GP | 2 |
| Herzig, RH | 2 |
| Fernández-Jiménez, MC | 2 |
| Ojeda, E | 1 |
| de Bustos, JG | 1 |
| Aguado, MJ | 1 |
| Nieto, Y | 1 |
| Cagnoni, PJ | 1 |
| Shpall, EJ | 1 |
| Xu, X | 1 |
| Murphy, J | 1 |
| Vredenburgh, J | 1 |
| Chao, NJ | 1 |
| Bearman, SI | 1 |
| Jones, RB | 1 |
| Heald, PW | 1 |
| Glusac, EJ | 1 |
| Decaudin, D | 1 |
| Brousse, N | 1 |
| Brice, P | 2 |
| Haioun, C | 1 |
| Van Hoof, A | 1 |
| Souleau, B | 1 |
| Quesnel, B | 1 |
| Goodman, S | 1 |
| Brandt, SJ | 1 |
| Morgan, DS | 1 |
| Macon, WR | 1 |
| McCurley, TL | 1 |
| Treleaven, J | 1 |
| Mainwaring, P | 1 |
| Kulkarni, S | 1 |
| Pandha, H | 1 |
| Bhagwati, N | 1 |
| Horton, C | 1 |
| Singhal, S | 1 |
| Mehta, J | 1 |
| Voso, MT | 1 |
| Martin, S | 1 |
| Hohaus, S | 2 |
| Abdallah, A | 1 |
| Schlenk, RF | 1 |
| Ho, AD | 1 |
| Haas, R | 2 |
| Argiris, A | 1 |
| Seropian, S | 1 |
| Cooper, DL | 1 |
| Stroiakovskiĭ, DL | 1 |
| Pivnik, AV | 1 |
| Shavlokhov, VS | 1 |
| Sotnikov, VM | 1 |
| Moiseeva, TN | 1 |
| Rasstrigin, NA | 1 |
| Margolin, OV | 1 |
| Efimov, IV | 1 |
| Dzhumabaeva, BT | 1 |
| Kaplanskaia, IB | 1 |
| Roshchina, LS | 1 |
| Hardan, I | 1 |
| Shpilberg, O | 1 |
| Raanani, P | 1 |
| Grotto, I | 1 |
| Ben-Bassat, I | 1 |
| Tauro, S | 1 |
| Dobie, D | 1 |
| Richardson, G | 1 |
| Hastings, M | 1 |
| Mahendra, P | 1 |
| Zelenetz, AD | 1 |
| Trippett, T | 1 |
| Hedrick, EE | 1 |
| Filippa, DA | 1 |
| Louie, D | 1 |
| Gonzales, M | 1 |
| Walits, J | 1 |
| Coady-Lyons, N | 1 |
| Qin, J | 1 |
| Frank, R | 1 |
| Bertino, JR | 1 |
| Goy, A | 1 |
| Noy, A | 1 |
| O'Brien, JP | 1 |
| Straus, D | 1 |
| Portlock, CS | 1 |
| Yahalom, J | 2 |
| Caballero, MD | 1 |
| Pérez-Simón, JA | 1 |
| García de Bustos, J | 1 |
| Vázquez, L | 1 |
| San Miguel, JF | 1 |
| Cao, TM | 1 |
| Horning, S | 1 |
| Negrin, RS | 1 |
| Hu, WW | 1 |
| Johnston, LJ | 1 |
| Taylor, TL | 1 |
| Shizuru, JA | 1 |
| Hoppe, RT | 1 |
| Brown, BW | 1 |
| Stockerl-Goldstein, KE | 1 |
| Mounier, N | 1 |
| Diviné, M | 1 |
| Stamatoullas, A | 1 |
| Reman, O | 1 |
| Voillat, L | 1 |
| Jaubert, J | 1 |
| Lederlin, P | 1 |
| Colin, P | 1 |
| Berger, F | 1 |
| Salles, G | 1 |
| Sextro, M | 1 |
| Carella, AM | 1 |
| Haenel, M | 1 |
| Boissevain, F | 1 |
| Zschaber, R | 1 |
| Müller, P | 1 |
| Kirchner, H | 1 |
| Lohri, A | 1 |
| Decker, S | 1 |
| Koch, B | 1 |
| Hasenclever, D | 1 |
| McIntire, KR | 1 |
| Vogel, CL | 1 |
| Primack, A | 1 |
| Waldmann, TA | 1 |
| Kyalwazi, SK | 1 |
| Alberts, DS | 1 |
| Durie, BG | 1 |
| Levin, VA | 2 |
| Hoffman, WF | 1 |
| Pischer, TL | 2 |
| Seager, ML | 1 |
| Boldrey, EB | 1 |
| Wilson, CB | 2 |
| Davis, R | 1 |
| Wara, W | 1 |
| Irwin, L | 1 |
| Kung, FH | 1 |
| Nythan, WL | 1 |
| Cuttner, J | 1 |
| Falkson, G | 1 |
| Lanzkowsky, P | 1 |
| Del Duca, V | 1 |
| Nawabi, IU | 1 |
| Koch, K | 1 |
| Pluess, H | 1 |
| Freeman, A | 1 |
| Burgert, EO | 1 |
| Leone, LA | 1 |
| Ruymann, F | 1 |
| Patterson, RB | 1 |
| Degnan, T | 1 |
| Hakami, N | 1 |
| Pajak, TF | 2 |
| Holland, J | 1 |
| Duffner, PK | 1 |
| Cohen, ME | 1 |
| Thomas, PR | 1 |
| Sinks, LF | 1 |
| Freeman, AI | 1 |
| Egerer, G | 1 |
| Ehrhardt, R | 1 |
| Witt, B | 1 |
| Hunstein, W | 1 |
| Crilley, P | 1 |
| Ciobanu, N | 1 |
| Fox, RM | 1 |
| Shina, DC | 1 |
| Bulova, SI | 1 |
| Gucalp, R | 1 |
| Topolsky, D | 1 |
| Kessinger, A | 1 |
| Barnett, MJ | 1 |
| Fairey, RN | 1 |
| Klingemann, HG | 1 |
| LeMaistre, CF | 1 |
| Gulati, S | 1 |
| Gaspard, MH | 1 |
| Maraninchi, D | 2 |
| Stoppa, AM | 1 |
| Gastaut, JA | 1 |
| Michel, G | 1 |
| Tubiana, N | 1 |
| Blaise, D | 1 |
| Novakovitch, G | 2 |
| Rossi, JF | 1 |
| Weiller, PJ | 1 |
| Jagannath, S | 2 |
| Dicke, KA | 2 |
| Cabanillas, FF | 1 |
| Horwitz, LJ | 2 |
| Vellekoop, L | 2 |
| Zander, AR | 2 |
| Spitzer, G | 2 |
| Pico, JL | 1 |
| Benhamou, E | 1 |
| Mascret, B | 1 |
| Ghalie, R | 1 |
| Hayat, M | 1 |
| Keating, M | 1 |
| McCredie, KB | 1 |
| McIntyre, OR | 1 |
| Kyle, RA | 1 |
| Cornwell, GG | 1 |
| Leone, L | 1 |
| McLaren, JH | 1 |
| Papac, RJ | 1 |
| Nordentoft, AM | 1 |
| Jensen, KB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase III Rituxan/BEAM vs. Bexxar/BEAM With Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-cell Non-Hodgkin's Lymphoma (BMTCTN0401)[NCT00329030] | Phase 3 | 224 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Phase II Trial of Gliadel Plus 06-Benzylguanine for Patients With Recurrent Glioblastoma Multiforme[NCT00362921] | Phase 2 | 52 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| A Pilot Study of Peripheral Blood Stem Cell Transplantation (PBSCT) After Preparative Therapy Consisting of Cyclophosphamide, BCNU, and Etoposide (CBV) for Recurrent and Primarily Refractory Hodgkin's and Non-Hodgkin's Lymphoma[NCT00002941] | Phase 2 | 69 participants (Actual) | Interventional | 1998-04-30 | Completed | ||
| High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial[NCT02531841] | Phase 3 | 250 participants (Anticipated) | Interventional | 2014-07-31 | Recruiting | ||
| The Role of Conformal External Beam Radiotherapy in the Management of Patients With Bulky Disease Undergoing Y90-Ibritumomab Tiuxetan (Zevalin) Radio-immunotherapy for Indolent B-cell Non-Hodgkin's Lymphoma[NCT00271050] | Phase 1 | 12 participants (Anticipated) | Interventional | 2005-12-31 | Completed | ||
| Safety and Efficacy of Ibritumomab Tiuxetan (Zevalin®) in Association With a Fludarabine Based Reduced Conditioning Regimen and Allogenic Stem Cell Support in Chemo-sensitive Relapsed CD20 Positive Aggressive Non-Hodgkin's Lymphoma Patients.[NCT00607854] | Phase 2 | 31 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A Phase I Clinical Trial of T-Cells Targeting CD19 and CD22 for Subjects With CD19-positive Acute Lymphoblastic Leukemia[NCT04303520] | Phase 1 | 20 participants (Anticipated) | Interventional | 2018-05-03 | Recruiting | ||
| Phase Ib-IIA Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence[NCT02681302] | Phase 1/Phase 2 | 35 participants (Actual) | Interventional | 2016-06-07 | Active, not recruiting | ||
| Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma： a Single-arm, Single-centre, Open-label Trial[NCT05786989] | Phase 4 | 32 participants (Anticipated) | Interventional | 2023-02-28 | Recruiting | ||
| Phase II Trial Investigating Tailoring First-Line Therapy For Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma Based on Mid-Treatment Positron Emission Tomography (PET) Scan Results[NCT00324467] | Phase 2 | 150 participants (Actual) | Interventional | 2006-08-31 | Active, not recruiting | ||
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| A Randomized Phase II Trial Comparing BeEAM With BEAM as Conditioning Regimen for Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)[NCT02278796] | Phase 2 | 108 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| A Phase II Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma[NCT01466868] | Phase 2 | 22 participants (Actual) | Interventional | 2011-11-30 | Terminated (stopped due to Regarding the comments of the iDSMB, the sponsor decided to stop the inclusions) | ||
| Targeted Intensification by a New Preparative Regimen for Patients With Low-Grade B-Cell Lymphoma Utilizing Standard-Dose Yttrium-90 Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy (RIT) Combined With High-Dose Beam Followed by Autologous Stem Cell Tran[NCT00138086] | Phase 2 | 75 participants | Interventional | 2005-03-31 | Completed | ||
| Randomized Study of ICE Plus RITUXIMAB Versus DHAP Plus Rituximab in Previously Treated Patients With Diffuse Large B-cell Lymphoma, Followed by Randomized Maintenance With Rituximab[NCT00137995] | Phase 3 | 481 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| A Phase II, Multicenter, Prospective, Non-randomised, Open-label, Clinical Trial to Evaluate Effectiveness and Safety of BeEAC Conditioning Regimen in Malignant Lymphoma Subjects With Indications to Autologous Hematopoietic Stem-cell Transplantation[NCT03315520] | Phase 2 | 100 participants (Anticipated) | Interventional | 2016-01-22 | Recruiting | ||
| Phase I/II Trial of Yttrium-90-labeled Daclizumab (Anti-CD25) Radioimmunotherapy With High-dose BEAM Chemotherapy and Autologous Hematopoietic Stem Cell Rescue in Recurrent and Refractory Hodgkin's Lymphoma[NCT01468311] | Phase 1/Phase 2 | 6 participants (Actual) | Interventional | 2011-10-11 | Terminated (stopped due to Poor enrollment and ability to radioconjugate Daclizumab. Neither Center for Cancer Research (CCR) or Nuclear Medicine/Radiology wanted to do the facilities upgrade and hire personnel needed to radioconjugate the drug at the Clinical Center.) | ||
| Phase II Study of Intensive Carmustine and Etoposide With Cisplatin or Cyclophosphamide, Followed By Rescue With Autologous Bone Marrow Treated In Vitro With Etoposide and/or Peripheral Blood Stem Cells Mobilized With Filgrastim (G-CSF) or Sargramostim (G[NCT00002461] | Phase 2 | 35 participants (Actual) | Interventional | 1988-04-30 | Completed | ||
| Feasibility Study of Interleukin 1-Alpha With Ifosfamide, CBDCA, and Etoposide With Autologous Bone Marrow Transplant in Metastatic Carcinoma and Lymphoma[NCT00001270] | Phase 1 | 85 participants | Interventional | 1991-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Mucositis severity will be scored per the modified Oral Mucositis Assessment Scale (OMAS) scoring system on a scale of 0 - 4, where 0 equals normal mucosa and 4 equals severe mucosa. (NCT00329030)
Timeframe: Day 21
| Intervention | scores on a scale (Median) |
|---|---|
| B-BEAM | 0.72 |
| R-BEAM | 0.31 |
(NCT00329030)
Timeframe: Day 100 and 2 years
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Day 100 | 2 years | |
| B-BEAM | 69.9 | 48.5 |
| R-BEAM | 71.0 | 43.9 |
Hematologic function will be defined as ANC > 1,500 neutrophils/μL, hemoglobin > 10 g/dL without transfusion support, and platelet count > 100,000/μL without transfusion support. (NCT00329030)
Timeframe: 100 days, 1 year
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Day 100 | 1 year | |
| B-BEAM | 34.8 | 64.0 |
| R-BEAM | 38.5 | 58.9 |
Tests to be performed on peripheral blood include CD2, CD3, CD4, CD8, CD19, CD3+/CD25+, CD45 RA/RO, CD56+/CD3-. (NCT00329030)
Timeframe: 1 year
| Intervention | cells/uL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| CD2 (cells/uL) | CD3 (cells/uL) | CD4 (cells/uL) | CD8 (cells/uL) | CD19 (cells/uL) | CD3+/CD25+ (cells/uL) | CD45RA (cells/uL) | CD45RO (cells/uL) | CD56+/CD3- (cells/uL) | |
| B-BEAM | 1006.0 | 921.8 | 342.8 | 558.5 | 143.4 | 112.2 | 469.3 | 476.2 | 125.1 |
| R-BEAM | 1024.9 | 990.3 | 286.1 | 697.7 | 140.8 | 118.0 | 579.8 | 727.8 | 130.5 |
Tests to be performed on peripheral blood for quantitative immunoglobulins include IgM, IgG and IgA. (NCT00329030)
Timeframe: 1 year
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| IgA (mg/dL) | IgG (mg/dL) | IgM (mg/dL) | |
| B-BEAM | 68.5 | 619.6 | 51.0 |
| R-BEAM | 85.0 | 643.8 | 79.0 |
(NCT00329030)
Timeframe: 1 year
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| 1 Infection | 2 Infections | 3 Infections | 4 Infections | 5 Infections | 6-10 Infections | >10 Infections | |
| B-BEAM | 38 | 14 | 5 | 3 | 1 | 6 | 0 |
| R-BEAM | 35 | 11 | 7 | 4 | 0 | 2 | 1 |
The time to this event is measured from randomization. Deaths without relapse/progression are considered as a competing risk. Surviving patients with no history of relapse/progression are censored at time of last follow-up. (NCT00329030)
Timeframe: 1 and 2 years
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 1 year | 2 years | |
| B-BEAM | 39.6 | 44.2 |
| R-BEAM | 40.7 | 47.4 |
Time to neutrophil recovery will be the first of two consecutive days of > 500 neutrophils/μL following the expected nadir. (NCT00329030)
Timeframe: Day 28 and Day 60
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Day 28 | Day 60 | |
| B-BEAM | 96.1 | 96.1 |
| R-BEAM | 93.5 | 95.3 |
The event is death from any cause. The time to this event is the time from randomization to death or last follow-up. Surviving patients are censored at the time of last observation (NCT00329030)
Timeframe: 1 and 2 years
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 1 year | 2 years | |
| B-BEAM | 68.5 | 60.1 |
| R-BEAM | 73.7 | 66.3 |
(NCT00329030)
Timeframe: 100 and 180 days
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Day 100 | Day 180 | |
| B-BEAM | 83.5 | 84.5 |
| R-BEAM | 82.2 | 83.2 |
Patients are considered a failure for this endpoint if they die, relapse/progress, or receive anti-lymphoma therapy, other than post-transplant consolidative localized radiation (maximum 3 sites) to sites of prior bulk disease pre-transplant (> 3cm). The time to this event is the time from randomization until death, relapse/progression, receipt of anti-lymphoma therapy, or last follow up, whichever comes first. (NCT00329030)
Timeframe: 1 and 2 years
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 1 year | 2 years | |
| B-BEAM | 53.2 | 48.6 |
| R-BEAM | 56.6 | 49.0 |
TRM is defined as death occurring in a patient from causes other than relapse or progression (NCT00329030)
Timeframe: 1 and 2 years
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 1 year | 2 years | |
| B-BEAM | 5.9 | 5.9 |
| R-BEAM | 2.9 | 3.9 |
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
Complete response rate is defined as the time it takes a participant to achieve a complete response. Response is assessed by the Revised Response Criteria for Malignant Lymphoma. Complete response requires all of the following: complete disappearance of all detectable clinical evidence of disease and disease related symptoms if present before therapy. A post treatment residual mass is permitted as long as it is positron emission tomography (PET) negative. If a pretreatment PET scan was negative, all lymph nodes and nodal masses must have regressed on computed tomography (CT) to normal size (<1.5 cm in their greatest transverse diameter for nodes >1.5 cm before therapy); Previously involved nodes that were 1.1 to 1.5 cm in their long axis and more than 1.0 cm in their short axis before treatment must have decreased to <1.0 cm in their short axis after treatment. (NCT01468311)
Timeframe: 20 months post autologous stem cell transplant
| Intervention | months (Median) |
|---|---|
| Yttrium-90-labeled Daclizumab + Chemotherapy | 7.5 |
DFS is defined as the amount of time participants remain disease free. (NCT01468311)
Timeframe: DFS is evaluated at day 100 post autologous stem cell transplant, then 1-4 times yearly for 5 years
| Intervention | months (Median) |
|---|---|
| Yttrium-90-labeled Daclizumab + Chemotherapy | 36 |
Patients who develop either a Common Terminology Criteria in Adverse Events (CTCAE) v4.0 grade 3 or greater non-hematologic toxicity, with the exception of fatigue, of more than 5 days duration possibly, probably or definitely related to the infusion of 90Y-daclizumab prior to the start of Carmustine, Etoposide, Cytarabine, [Ara-C, Cytosine Arabinoside] and Melphalan (BEAM) chemotherapy (Day - 6) will have developed by definition a dose-limiting toxicity (DLT). (NCT01468311)
Timeframe: 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Yttrium-90-labeled Daclizumab + Chemotherapy | 0 |
Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01468311)
Timeframe: 30 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Yttrium-90-labeled Daclizumab + Chemotherapy | 3 |
Overall survival is defined as the time from the date of registration to the date of death due to any cause or if no death occurs to the last documented information on the patient. (NCT01468311)
Timeframe: OS is evaluated at day 100 post autologous stem cell transplant, then 1-4 times yearly for 5 years
| Intervention | months (Median) |
|---|---|
| Yttrium-90-labeled Daclizumab + Chemotherapy | 36 |
4 reviews available for carmustine and Recrudescence
| Article | Year |
|---|---|
Autologous Stem Cell Transplantation in the Management of Relapsed Non-Hodgkin Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials, Phase III as Topic; Cyc | 2021 |
Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; D | 2016 |
Autologous stem cell transplantation in patients with mantle cell lymphoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modal | 2002 |
Intensive therapy and autotransplantation in Hodgkin's disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplantation; C | 1994 |
51 trials available for carmustine and Recrudescence
| Article | Year |
|---|---|
Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Car | 2018 |
Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL).
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity | 2019 |
Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT C
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-D | 2013 |
Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carmustine; | 2014 |
Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Decanoic A | 2009 |
Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <65 years with poor prognosis histologically aggressive NHL.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamid | 2010 |
Autologous peripheral blood stem cell transplantation in children with refractory or relapsed lymphoma: results of Children's Oncology Group study A5962.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Child, Preschool; Cyc | 2011 |
Clinical outcome of autologous peripheral blood stem cell transplantation in opticospinal and conventional forms of secondary progressive multiple sclerosis in a Chinese population.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; China; Cytarabine; Disease-Free S | 2011 |
Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue.
Topics: Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combin | 2011 |
A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma.
Topics: Adult; Aged; Analysis of Variance; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Prot | 2012 |
Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmus | 2012 |
Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Disease-Free Survival | 2013 |
Phase II trial of 131-Iodine tositumomab with high-dose chemotherapy and autologous stem cell transplantation for relapsed diffuse large B cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pro | 2013 |
A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's diseas
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; E | 2002 |
High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Blood Plate | 2003 |
Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation.
Topics: Adolescent; Adoptive Transfer; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Pro | 2003 |
Autologous peripheral blood stem cell transplantation with BCVAC conditioning in childhood acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Ant | 2004 |
Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; | 2004 |
Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG).
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2005 |
First-line autologous stem cell transplantation in primary CNS lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neop | 2005 |
Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carm | 2006 |
Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cyclophosphamide; Cyta | 2006 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Phase I/II study incorporating intravenous hydroxyurea into high-dose chemotherapy for patients with primary refractory or relapsed and refractory intermediate-grade and high-grade malignant lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1995 |
Primary non-Hodgkin's lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemothera | 1996 |
High lactate dehydrogenase level is associated with an adverse outlook in autografting for Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1996 |
Autologous bone marrow transplantation for patients with acute myeloblastic leukemia in relapse after autologous blood stem cell transplantation.
Topics: Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transpl | 1996 |
Treatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation. A phase I-II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine | 1997 |
Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Caus | 1998 |
High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Thera | 1998 |
Long-term results of autologous marrow transplantation for relapsed or refractory male or female germ cell tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cisplati | 1998 |
The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1998 |
The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1998 |
The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1998 |
The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1998 |
Dexa-BEAM is not effective in patients with relapsed or resistant aggressive high-grade non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dexamethasone; Drug R | 1999 |
Salvage chemotherapy with IAPVP-16 for advanced refractory or relapsed follicular lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Disease-F | 1999 |
Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin's disease: a phase II study from the North American Marrow
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality The | 1999 |
Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carmustine; | 1999 |
Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Carmustine; Combined Mo | 2000 |
Intensified preparative regimens and autologous transplantation in refractory or relapsed intermediate grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modali | 2000 |
The role of autologous transplantation in patients with multiple myeloma aged 65 years and over.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Chem | 2000 |
A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cisplatin; Cyc | 2001 |
Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dis | 2002 |
Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cause of Death; Cytar | 2002 |
Preliminary results of a phase III comparison study of BCNU, hydroxyurea and radiation to BCNU and radiation.
Topics: Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Therapy, Combination; Glioblastoma; Glio | 1979 |
Vincristine, prednisone and L-asparaginase in the induction of remission in children with acute lymphoblastic leukemia following relapse.
Topics: Adolescent; Adult; Antineoplastic Agents; Asparaginase; Bone Marrow; Brain Neoplasms; Carmustine; Ch | 1978 |
Remission maintenance therapy for multiple myeloma.
Topics: Bone Neoplasms; Carmustine; Drug Therapy, Combination; Female; Humans; Male; Melphalan; Middle Aged; | 1975 |
Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) subsequent to chemotherapy improves collection of blood stem cells for autografting in patients not eligible for bone marrow harvest.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytara | 1992 |
High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow | 1992 |
Response rate and survival in myeloma patients receiving prednisone alone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Female; Humans; Male; Melphalan; Middle | 1985 |
69 other studies available for carmustine and Recrudescence
| Article | Year |
|---|---|
Impact of thiotepa dose-intensity in primary diffuse large B-cell lymphoma of the central nervous system undergoing autologous hematopoietic cell transplant with thiotepa/carmustine conditioning.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Central Nervous Syste | 2023 |
Allogenic hematopoietic stem cell transplantation for prolonged bone marrow aplasia after chimeric antigen receptor (CAR) T-cell therapy for relapsed diffuse large B-cell lymphoma.
Topics: Adrenal Cortex Hormones; Allografts; Anemia, Aplastic; Antibodies, Monoclonal, Humanized; Antigens, | 2020 |
High-dose Benda-EAM versus BEAM in patients with relapsed/refractory classical Hodgkin lymphoma undergoing autologous stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Eto | 2019 |
Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Child; Chlorambuc | 2014 |
Assessing response using 99mTc-MIBI early after interstitial chemotherapy with carmustine-loaded polymers in glioblastoma multiforme: preliminary results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carmustine; Female; Glioblastoma; Humans; Mal | 2014 |
Impressive response to pegylated liposomal doxorubicin after allogeneic transplantation in a multi-relapsed Hodgkin's lymphoma.
Topics: Allografts; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bendamustin | 2016 |
Improved outcomes after autologous bone marrow transplantation for children with relapsed or refractory Hodgkin lymphoma: twenty years experience at a single institution.
Topics: Adolescent; Adult; Bone Marrow Transplantation; Carmustine; Child; Cyclophosphamide; Etoposide; Fema | 2015 |
High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cy | 2015 |
Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah's Witnesses.
Topics: Adult; Aged; Aminocaproic Acid; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; C | 2015 |
Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cyta | 2015 |
Alemtuzumab-BEAM as conditioning for allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma: a single-center analysis.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocol | 2016 |
Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carmustine; Chi-Square Dis | 2008 |
Autologous stem cell transplant in a patient with Down syndrome and relapsed Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Child; Combined Modality Ther | 2009 |
Consensus conference on the use of 90-yttrium-ibritumomab tiuxetan therapy in clinical practice. A project of the Italian society of hematology.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine | 2010 |
Immunomagnetic selection of CD34(+) cells carried out in cryopreserved cell concentrates from a paediatric patient affected with non-Hodgkin lymphoma.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Preservation; Carmustine; Cell | 2010 |
Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide | 2012 |
Radiation-free allogeneic conditioning with fludarabine, carmustine, and thiotepa for acute lymphoblastic leukemia and other hematologic malignancies necessitating enhanced central nervous system activity.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Carmustine; Central Nervous System; Cyc | 2012 |
[Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transp
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cladribine; Combined Modality The | 2012 |
Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma--a long-term follow-up study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Central Nervous System Neop | 2012 |
Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission.
Topics: Adolescent; Amsacrine; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Ma | 2003 |
High-dose chemotherapy with autologous stem cell rescue in children with retinoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine; Child; Child, Preschool; Co | 2003 |
Treatment of lymphoma relapses after allogeneic hematopoietic stem cell transplantation with intensive chemotherapy followed by infusion of hematopoietic stem cell from the original donor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Etoposide; Female; Gr | 2003 |
Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamid | 2005 |
Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carm | 2005 |
Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cytarabine; Deoxycytid | 2006 |
Treatment options in relapsed or refractory Hodgkin disease patients: the mini-BEAM regimen does exist too.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Drug Administration Schedule | 2006 |
Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Deoxycyti | 2007 |
High-dose therapy and autologous stem cell transplantation for Hodgkin's lymphoma in relapse or failure after initial chemotherapy : results of the Centre National de Greffe de Moelle Osseuse de Tunis.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine | 2007 |
A second autologous transplant may be efficacious in selected patients with Hodgkin's lymphoma relapsing after a previous autograft.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Female; Follow-Up Stu | 2007 |
Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antin | 2008 |
Intracavitary chemotherapy (Gliadel) and oral low-dose etoposide for recurrent anaplastic ependymoma.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Biocompatible Materials; Brain; Brain Neoplasms; Carm | 2008 |
Addition of cisplatin and bleomycin to vincristine-carmustine-doxorubicin-prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Doxorubicin; Drug | 1984 |
High-dose BCNU with autologous bone marrow rescue for recurrent glioblastoma multiforme.
Topics: Adolescent; Adult; Bone Marrow; Bone Marrow Transplantation; Brain Neoplasms; Carmustine; Female; Gl | 1981 |
High-dose polychemotherapy with autologous bone marrow transplantation in children with relapsed lymphomas.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; | 1984 |
High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation | 1995 |
Chronic relapsing polyradiculoneuropathy in IgG lambda monoclonal gammopathy of undetermined significance (MGUS)--complete remission following carmustine treatment.
Topics: Adult; Carmustine; Combined Modality Therapy; Drug Therapy, Combination; Female; Follow-Up Studies; | 1995 |
Total body irradiation and high-dose cyclophosphamide, BCNU and VP-16 (CBV) as a new preparatory regimen for allogeneic bone marrow transplantation in patients with advanced hematologic malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1994 |
Factors influencing prognosis after dose-intensive therapy for recurrent or refractory Hodgkin's disease. Results of sequential trials: a case for treating patients with resistant disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carb | 1995 |
Treatment of relapsed non-Hodgkin's lymphoma after BEAM chemotherapy and autologous transplantation by BU/CY chemotherapy and salvage transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Ther | 1997 |
[Hemopoietic stem cell transplantation in lymphogranulomatosis].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Carmustine; Ch | 1997 |
Salvage chemotherapy with mini-BEAM for relapsed or refractory non-Hodgkin's lymphoma prior to autologous bone marrow transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation | 1997 |
High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation | 1998 |
[Superhigh-dosage chemotherapy with the transplantation of autologous hemopoietic precursor cells in patients with a prognostically unfavorable relapse and resistant course of lymphogranulomatosis].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality The | 1997 |
Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation--results of a retrospective analysis on 120 patients autografted in a single institution.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Combined Mod | 1998 |
Autotransplantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclop | 1998 |
Haemopoietic cell transplantation activity and results: a single institution experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Graft vs Host Disease; Hemat | 1998 |
O(6)-methylguanine-DNA methyltransferase gene (MGMT) expression in human glioblastomas in relation to patient characteristics and p53 accumulation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Chemotherapy, Adj | 1999 |
A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Mal | 1999 |
Unilesional cutaneous T-cell lymphoma: clinical features, therapy, and follow-up of 10 patients with a treatment-responsive mycosis fungoides variant.
Topics: Administration, Topical; Adult; Aged; Antineoplastic Agents, Alkylating; Carmustine; Female; Humans; | 2000 |
Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytara | 2000 |
High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combi | 2000 |
[The 1st results of the combined therapy of recurrent and refractory forms of lymphogranulomatosis (polychemotherapy, radiation therapy and the removal of the residual mediastinal formation)].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chemotherapy, Adjuvan | 2000 |
[High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Combined Modality Ther | 2000 |
Recurrent penicillin-resistant pneumococcal sepsis after matched unrelated donor (MUD) transplantation for refractory T cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bone Marrow Transplantation; Carm | 2000 |
Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Blood Sedimentation; | 2001 |
High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; | 2001 |
Effect of surgical and chemotherapeutic treatment on alpha-fetoprotein levels in patients with hepatocellular carcinoma.
Topics: alpha-Fetoproteins; Carmustine; Fetal Proteins; Humans; Liver Neoplasms; Methotrexate; Recurrence | 1976 |
Doxorubicin/B.C.N.U. chemotherapy for multiple myeloma in relapse.
Topics: Alkylating Agents; Blood Cell Count; Carmustine; Cell Count; Doxorubicin; Drug Therapy, Combination; | 1976 |
BCNU-5-fluorouracil combination therapy for recurrent malignant brain tumors.
Topics: Astrocytoma; Bone Marrow; Brain Neoplasms; Carmustine; Drug Therapy, Combination; Fluorouracil; Glio | 1978 |
Combination chemotherapy in recurrent medulloblastoma.
Topics: Adolescent; Antineoplastic Agents; Brain Neoplasms; Carmustine; Child; Child, Preschool; Dexamethaso | 1979 |
High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Car | 1991 |
Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease.
Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow | 1991 |
Autologous bone marrow transplantation for refractory or relapsed Hodgkin's disease: the Memorial Sloan-Kettering Cancer Center experience using high-dose chemotherapy with or without hyperfractionated accelerated total lymphoid irradiation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1991 |
Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1988 |
High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1986 |
Modified chemotherapy with carmustine, cytarabine, cyclophosphamide, and 6-thioguanine (BACT) and autologous bone marrow transplantation in 24 poor-risk patients with acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1986 |
High-dose cyclophosphamide, BCNU, and etoposide followed by autologous bone marrow rescue as treatment for adult acute leukemia in relapse.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transp | 1986 |
Prognosis and survival with extranodal Hodgkin's disease.
Topics: Adult; Carmustine; Chlorambucil; Cyclophosphamide; Drug Therapy, Combination; Hodgkin Disease; Human | 1974 |
Combination chemotherapy in Hodgkin's disease.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carmustine; Child; Female; Hodgkin Disease; Humans; | 1973 |